PriceTargets.com logo

NASDAQ:CELC - Celcuity Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.40
  • Forecasted Upside: 164.74 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$15.26 As of 11/26/2021 01:00 AM ET
▼ -1.24 (-7.52%)

This chart shows the closing price for CELC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celcuity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CELC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CELC

Analyst Price Target is $40.40
▲ +164.74% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Celcuity in the last 3 months. The average price target is $40.40, with a high forecast of $50.00 and a low forecast of $24.00. The average price target represents a 164.74% upside from the last price of $15.26.

This chart shows the closing price for CELC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Celcuity. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/8/2021Canaccord GenuityInitiated CoverageBuy$50.00Medium
9/7/2021Jefferies Financial GroupInitiated CoverageBuy$48.00Medium
8/10/2021Needham & Company LLCInitiated CoverageBuy$50.00High
7/29/2021CowenInitiated CoverageOutperformHigh
7/27/2021Needham & Company LLCInitiated CoverageBuy$50.00High
4/12/2021HC WainwrightBoost Price TargetBuy$19.00 ➝ $30.00High
2/17/2021Craig HallumBoost Price TargetBuy$19.00 ➝ $24.00Low
2/17/2021HC WainwrightReiterated RatingBuy$18.00 ➝ $19.00Low
1/28/2021HC WainwrightBoost Price TargetBuy$14.00 ➝ $18.00High
12/24/2020Craig HallumBoost Price TargetBuy$16.00 ➝ $19.00N/A
12/24/2020HC WainwrightBoost Price TargetBuy$11.00 ➝ $14.00N/A
8/11/2020HC WainwrightReiterated RatingBuy$11.00Low
7/14/2020HC WainwrightReiterated RatingBuy$11.00Low
6/23/2020HC WainwrightReiterated RatingBuy$11.00High
5/11/2020Craig HallumInitiated CoverageBuyHigh
5/8/2020HC WainwrightReiterated RatingBuy$19.00 ➝ $11.00High
3/13/2020HC WainwrightReiterated RatingBuy$36.00 ➝ $19.00High
12/13/2019HC WainwrightReiterated RatingBuy$36.00Low
5/8/2019HC WainwrightSet Price TargetBuy$36.00High
12/10/2018HC WainwrightSet Price TargetBuy$36.00High
11/26/2018HC WainwrightSet Price TargetBuy$36.00Low
11/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$36.00Low
11/14/2018Craig HallumBoost Price TargetBuy$30.00 ➝ $35.00High
10/16/2017Craig HallumInitiated CoverageBuyN/A
(Data available from 11/27/2016 forward)

News Sentiment Rating

-0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
7/30/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/29/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
10/28/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Celcuity logo
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Read More

Today's Range

Now: $15.26
Low: $14.97
High: $15.94

50 Day Range

MA: $17.75
Low: $14.68
High: $20.50

52 Week Range

Now: $15.26
Low: $8.75
High: $33.01

Volume

15,711 shs

Average Volume

160,248 shs

Market Capitalization

$227.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Celcuity?

The following Wall Street analysts have issued research reports on Celcuity in the last year: Canaccord Genuity, Cowen Inc, Craig Hallum, HC Wainwright, Jefferies Financial Group Inc., Needham & Company LLC, and Zacks Investment Research.
View the latest analyst ratings for CELC.

What is the current price target for Celcuity?

5 Wall Street analysts have set twelve-month price targets for Celcuity in the last year. Their average twelve-month price target is $40.40, suggesting a possible upside of 164.7%. Canaccord Genuity has the highest price target set, predicting CELC will reach $50.00 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $24.00 for Celcuity in the next year.
View the latest price targets for CELC.

What is the current consensus analyst rating for Celcuity?

Celcuity currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CELC will outperform the market and that investors should add to their positions of Celcuity.
View the latest ratings for CELC.

What other companies compete with Celcuity?

Other companies that are similar to Celcuity include Renalytix AI, Personalis, Progenity, DermTech, Viridian Therapeutics, Sera Prognostics, Exagen, Enzo Biochem, Centogene, Biocept, OpGen, Vyant Bio, Psychemedics, CannLabs and PharmChem.

How do I contact Celcuity's investor relations team?

Celcuity's physical mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The company's listed phone number is (763) 392-0767. The official website for Celcuity is www.celcuity.com.